Displaying drugs 1526 - 1550 of 2345 in total
S-8510
S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Investigational
XL-888
XL888 has been used in trials studying the treatment of Cancer and Melanoma.
Investigational
Matched Iupac: … 5-{[(2R)-butan-2-yl]amino}-N1-[(1R,3R,5S)-8-(5-cyclopropanecarbonylpyridin-2-yl)-8-azabicyclo[3.2.1]octan …
Zinc mesoporphyrin
Investigational
Matched Iupac: … 4,10,15,20-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1,3(24 …
Selicrelumab
Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Investigational
Olpasiran
Olpasiran is under investigation in clinical trial NCT05581303 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (Ocean(a)) - Outcomes Trial).
Investigational
Sitamaquine
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Iupac: … N-[6-(diethylamino)hexyl]-6-methoxy-4-methylquinolin-8-amine …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
BBP-812
Investigational
VTX-801
VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). It is being investigated in Wilson Disease.
Investigational
BAY-876
Experimental
cis-tetracosenoyl sulfatide
Experimental
CM-101
Investigational
MK-8719
Investigational
Strontium cation Sr-89
Experimental
Cendakimab
Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
Investigational
ARCT-810
ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.
Investigational
ROX-888
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
AS-8112
AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.
Experimental
MK-8776
Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia, Lymphoma, Non-Hodgkin, and Myelogenous Leukemia, Acute, among others.
Investigational
OMS-824
Investigational
RC88
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
Acetrizoic acid
Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th,...
Withdrawn
Displaying drugs 1526 - 1550 of 2345 in total